Measuring Circulating Tumor Cells As a Surrogate End Point for Adjuvant Therapy of Breast Cancer: What Do They Mean and What Should We Do About Them?

This publication has 31 references indexed in Scilit:

• Monitoring the Response of Circulating Epithelial Tumor Cells to Adjuvant Chemotherapy in Breast Cancer Allows Detection of Patients at Risk of Early Relapse
  Journal of Clinical Oncology, 2008
• The measurement and therapeutic implications of circulating tumour cells in breast cancer
  British Journal of Cancer, 2005
• Complex of urokinase‐type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node–negative breast carcinoma
  Cancer, 2004
• Predictive Impact of Urokinase-Type Plasminogen Activator
  Cancer Research, 2004
• Axillary Lymph Node Status, But Not Tumor Size, Predicts Locoregional Recurrence and Overall Survival After Mastectomy for Breast Cancer
  Annals of Surgery, 2003
• Hormone Receptors as Prognostic Factors in Female: Breast Cancer
  Annals of Medicine, 1991
• HER-2/neu oncogene protein and prognosis in breast cancer.
  Journal of Clinical Oncology, 1989
• Pathologic findings from the national surgical adjuvant project for breast cancers (protocol no. 4) X. Discriminants for tenth year treatment failure
  Cancer, 1984
• Cancer Of The Colon
  Annals of Surgery, 1967
• MORTALITY AMONG SHEEP AFTER A SEVERE THUNDERSTORM.
  Australian Veterinary Journal, 1938